ILU Stock Chart & Stats
€190.56
€0.74(0.60%)
At close: 4:00 PM EDT
€190.56
€0.74(0.60%)
Day’s Range― - ―
52-Week Range€77.67 - €216.30
Previous CloseN/A
Volume243.00
Average Volume (3M)91.00
Market Cap
€31.51B
Enterprise Value€28.37K
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€2.53B
Price to Earnings (P/E)44.3
Beta0.39
Next Earnings
Oct 29, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,000,000
10 Day Avg. Volume22
30 Day Avg. Volume91
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€174.95Price Target Upside-8.19% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)4.6
Revenue Forecast (FY)€3.98B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelIllumina's instrument base creates a recurring consumables engine: each sequencer supports repeat purchases of reagents, flow cells and sample-preparation products. As utilization expands, this model can deepen customer engagement and make revenue less dependent on one-time hardware placements over the next several quarters.
NovaSeq X AdoptionElevated NovaSeq X placements are expanding the installed base and shifting more sequencing volume onto the platform. Management expects this larger base to drive consumables pull-through into 2027, supporting a durable revenue stream beyond the initial instrument sale and reinforcing clinical adoption.
Strong Profitability And Cash GenerationThe recovery has produced substantial operating profitability and cash generation, giving Illumina resources to fund product development, support customer adoption and manage capital allocation. Strong free cash flow provides a meaningful financial cushion as the company pursues longer-term genomics growth.
Bears Say
Moderate-to-elevated LeverageLeverage is meaningful relative to the current equity base and reduces flexibility if earnings weaken again. Although the balance sheet is described as serviceable, debt obligations can constrain investment, buybacks and other capital-allocation choices during a softer operating cycle.
Research Consumables WeaknessPersistent weakness in research and applied consumables offsets clinical momentum and directly pressures utilization of Illumina's sequencing infrastructure. Continued declines would limit recurring pull-through, weigh on mix and make the company's growth profile more dependent on clinical conversion and large placements.
Earnings Durability Remains UnevenThe sharp swing from losses in 2023–2024 to strong TTM margins demonstrates recovery but also leaves questions about consistency across business cycles. Uneven earnings can make reinvestment and capital allocation less predictable, particularly if research demand or regional conditions deteriorate.
Illumina News
ILU FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €77.67 and its highest was €216.30 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €31.51B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 37 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported €1.126 earnings per share for the quarter, beating the consensus estimate of €1.054 by €0.072.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.17.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.126 in its last earnings report, beating expectations of €1.054. Following the earnings report the stock price went down -1.692%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in DE:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€174.95 (-8.19% Downside)
€174.95 (-8.19% Downside)
Blogger Sentiment
Bullish
DE:ILU Sentiment 64%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €380.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILU Company Deck
ILU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all DE:ILU earnings summariesILU Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILU Stock 12 Month Forecast
Average Price Target
€174.95
▼(-8.19% Downside)